CN107198708B - A kind of sunflower disc extract and its preparation method and use - Google Patents
A kind of sunflower disc extract and its preparation method and use Download PDFInfo
- Publication number
- CN107198708B CN107198708B CN201710352702.XA CN201710352702A CN107198708B CN 107198708 B CN107198708 B CN 107198708B CN 201710352702 A CN201710352702 A CN 201710352702A CN 107198708 B CN107198708 B CN 107198708B
- Authority
- CN
- China
- Prior art keywords
- extract
- sunflower
- sunflower disc
- ethyl acetate
- petroleum ether
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 241000208818 Helianthus Species 0.000 title claims abstract description 56
- 235000003222 Helianthus annuus Nutrition 0.000 title claims abstract description 56
- 239000000284 extract Substances 0.000 title claims abstract description 49
- 238000002360 preparation method Methods 0.000 title claims abstract description 9
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 claims abstract description 21
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 claims abstract description 21
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 claims abstract description 21
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 claims abstract description 21
- 235000001368 chlorogenic acid Nutrition 0.000 claims abstract description 21
- 229940074393 chlorogenic acid Drugs 0.000 claims abstract description 21
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 claims abstract description 21
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 claims abstract description 21
- 229930003935 flavonoid Natural products 0.000 claims abstract description 7
- 150000002215 flavonoids Chemical class 0.000 claims abstract description 7
- 235000017173 flavonoids Nutrition 0.000 claims abstract description 7
- 239000003071 vasodilator agent Substances 0.000 claims abstract description 3
- 229940124549 vasodilator Drugs 0.000 claims abstract 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 82
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 16
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 10
- 239000003208 petroleum Substances 0.000 claims description 10
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 9
- 239000007788 liquid Substances 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- 239000002244 precipitate Substances 0.000 claims description 5
- 238000010992 reflux Methods 0.000 claims description 5
- 238000003810 ethyl acetate extraction Methods 0.000 claims description 4
- 238000010298 pulverizing process Methods 0.000 claims description 4
- 238000005119 centrifugation Methods 0.000 claims description 3
- 238000002390 rotary evaporation Methods 0.000 claims description 3
- 238000010025 steaming Methods 0.000 claims 2
- 210000004204 blood vessel Anatomy 0.000 claims 1
- 230000000916 dilatatory effect Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 5
- 230000000694 effects Effects 0.000 description 15
- 239000000243 solution Substances 0.000 description 15
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 11
- 235000005493 rutin Nutrition 0.000 description 11
- 229960004555 rutoside Drugs 0.000 description 11
- 238000002835 absorbance Methods 0.000 description 10
- 241000700159 Rattus Species 0.000 description 9
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 8
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 8
- IKGXIBQEEMLURG-NVPNHPEKSA-N rutin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-NVPNHPEKSA-N 0.000 description 8
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 8
- 239000000523 sample Substances 0.000 description 8
- 238000000605 extraction Methods 0.000 description 7
- 230000024883 vasodilation Effects 0.000 description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 210000002376 aorta thoracic Anatomy 0.000 description 6
- 210000003038 endothelium Anatomy 0.000 description 6
- 238000004445 quantitative analysis Methods 0.000 description 6
- 208000006906 Vascular Ring Diseases 0.000 description 5
- 230000001419 dependent effect Effects 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 238000001556 precipitation Methods 0.000 description 4
- 239000012086 standard solution Substances 0.000 description 4
- 210000000115 thoracic cavity Anatomy 0.000 description 4
- 230000000717 retained effect Effects 0.000 description 3
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 3
- 244000020551 Helianthus annuus Species 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 2
- 229960004373 acetylcholine Drugs 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- XEYBHCRIKKKOSS-UHFFFAOYSA-N disodium;azanylidyneoxidanium;iron(2+);pentacyanide Chemical compound [Na+].[Na+].[Fe+2].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].[O+]#N XEYBHCRIKKKOSS-UHFFFAOYSA-N 0.000 description 2
- 238000002224 dissection Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 238000012417 linear regression Methods 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 description 2
- 229960001802 phenylephrine Drugs 0.000 description 2
- 239000013558 reference substance Substances 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 229940083618 sodium nitroprusside Drugs 0.000 description 2
- 235000020238 sunflower seed Nutrition 0.000 description 2
- 230000000304 vasodilatating effect Effects 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 235000009161 Espostoa lanata Nutrition 0.000 description 1
- 240000001624 Espostoa lanata Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 239000007836 KH2PO4 Substances 0.000 description 1
- KCWZGJVSDFYRIX-YFKPBYRVSA-N N(gamma)-nitro-L-arginine methyl ester Chemical compound COC(=O)[C@@H](N)CCCN=C(N)N[N+]([O-])=O KCWZGJVSDFYRIX-YFKPBYRVSA-N 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 206010047141 Vasodilatation Diseases 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 230000003205 diastolic effect Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 239000002398 materia medica Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/35—Extraction with lipophilic solvents, e.g. Hexane or petrol ether
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
本发明涉及医药学领域,特别是涉及一种葵花盘提取物及其制备方法和用途。本发明的葵花盘提取物含总黄酮17.1±0.2wt%、绿原酸6.7±0.1wt%。本发明的葵花盘提取物可用于制备扩血管药物。The invention relates to the field of medicine, in particular to a sunflower disc extract and a preparation method and application thereof. The sunflower disc extract of the present invention contains 17.1±0.2wt% of total flavonoids and 6.7±0.1wt% of chlorogenic acid. The sunflower disc extract of the present invention can be used for preparing vasodilators.
Description
技术领域technical field
本发明涉及医药学领域,特别是涉及一种植物提取物及其制备方法和用途。The present invention relates to the field of medicine, in particular to a plant extract and its preparation method and use.
背景技术Background technique
葵花盘为脱去葵花籽的向日葵(Helianthus annuus L.),向日葵属于菊科向日葵属,为一年生草本植物,别名葵花,我国古籍上又叫西番莲、丈菊、迎阳花等。我国栽培向日葵至少已有近四百年的历史,过往人们会将脱去葵花籽的葵花盘当作废弃物燃烧掉,近年来葵花盘由于含有多种营养成分多被制作为饲料或用来提取果胶。葵花盘其实也是一味中药材,葵花盘,味甘、性寒、无毒,归肝经。功能祛风,平肝,清湿热,散滞气,益气补肾。《中华本草》中记载其有治疗高血压、头痛、头晕、耳鸣等症状的作用。The sunflower plate is the sunflower (Helianthus annuus L.) with the sunflower seeds removed. The sunflower belongs to the Asteraceae Helianthus genus and is an annual herb, also known as sunflower. Sunflower cultivation in my country has a history of at least four hundred years. In the past, people would burn sunflower trays with sunflower seeds removed as waste. In recent years, sunflower trays have been made into feed or used for extraction due to the fact that they contain a variety of nutrients. pectin. In fact, sunflower plate is also a blind Chinese medicinal material. Sunflower plate is sweet, cold in nature, non-toxic, and belongs to the liver meridian. Functions Dispel wind, calm liver, clear dampness and heat, disperse stagnant qi, nourish qi and invigorate kidney. "Chinese Materia Medica" records that it has the effect of treating high blood pressure, headache, dizziness, tinnitus and other symptoms.
向日葵作为我国重要的油料作物,种植面积广泛,其种子用作榨油,而花盘尚未开发利用,只是在民间验方中用作药物。研究表明,葵花盘具有降低血压的作用,然而目前对于其舒张血管的作用并无相关报道。As an important oil crop in my country, sunflower is widely planted, and its seeds are used for oil extraction, while the flower plate has not been developed and utilized, but is only used as a medicine in folk prescriptions. Studies have shown that sunflower disc has the effect of lowering blood pressure, but there is no relevant report on its vasodilatory effect.
发明内容SUMMARY OF THE INVENTION
本发明的目的旨在提供一种葵花盘提取物及其制备方法和舒张血管效果。The purpose of the present invention is to provide a sunflower disc extract and its preparation method and vasodilation effect.
具体而言,本发明的第一方面是提供了一种葵花盘提取物,所述葵花盘提取物含总黄酮16.9~17.3wt%、绿原酸6.6~6.8wt%。Specifically, the first aspect of the present invention provides a sunflower disc extract, the sunflower disc extract contains 16.9-17.3 wt % of total flavonoids and 6.6-6.8 wt % of chlorogenic acid.
在一优选例中,所述葵花盘提取物由如下方法制得:将葵花盘粉碎,通过回流装置以75%乙醇提取;将提取物旋蒸、离心去沉淀;石油醚—乙酸乙酯—正丁醇依次萃取,所述石油醚与乙酸乙酯萃取步骤保留下层液体,最后加入正丁醇,静置后分层,保留其上层提取液;将所得上层提取液旋蒸、离心去沉淀,得到正丁醇相提取物。In a preferred example, the sunflower disc extract is prepared by the following method: pulverizing the sunflower disc and extracting it with 75% ethanol through a reflux device; rotating the extract and centrifuging to remove the precipitation; petroleum ether-ethyl acetate-normal The butanol is extracted in turn, the petroleum ether and ethyl acetate extraction step retains the lower layer liquid, and finally n-butanol is added, and after standing, the layers are separated, and the upper layer extract is retained; n-Butanol phase extract.
本发明的第二方面是提供了一种上述的葵花盘提取物的制备方法,所述方法包括:将葵花盘粉碎,通过回流装置以75%乙醇提取;将提取物旋蒸、离心去沉淀;石油醚—乙酸乙酯—正丁醇依次萃取,所述石油醚与乙酸乙酯萃取步骤保留下层液体,最后加入正丁醇,静置后分层,保留其上层提取液;将所得上层提取液旋蒸、离心去沉淀,得到正丁醇相提取物。The second aspect of the present invention provides a method for preparing the above-mentioned sunflower disc extract, the method comprising: pulverizing the sunflower disc, extracting with 75% ethanol through a reflux device; rotating the extract and centrifuging to remove the precipitation; Petroleum ether-ethyl acetate-n-butanol are extracted in turn, the petroleum ether and ethyl acetate extraction step retains the lower layer liquid, and finally n-butanol is added, and after standing, the layers are separated, and the upper layer extract is retained; the obtained upper layer extract is Rotary evaporation and centrifugation to remove the precipitate to obtain n-butanol phase extract.
本发明还提供了上述葵花盘提取物在制备扩血管药物中的用途。The present invention also provides the use of the above sunflower disc extract in preparing a vasodilator drug.
本发明各个方面的细节将在随后的章节中得以详尽描述。通过下文以及权利要求的描述,本发明的特点、目的和优势将更为明显。The details of various aspects of the invention will be described in detail in subsequent sections. The features, objects and advantages of the present invention will become more apparent from the description below and in the claims.
附图说明Description of drawings
图1本发明的葵花盘正丁醇相提取物的芦丁标准曲线,说明芦丁浓度在0~640ug/ml范围内与吸光度线性良好;The rutin standard curve of Fig. 1 sunflower disc n-butanol phase extract of the present invention illustrates that the rutin concentration and the absorbance linearity are good in the range of 0~640ug/ml;
图2本发明的葵花盘正丁醇相提取物的绿原酸标准曲线,说明绿原酸浓度在0~128ug/ml范围内与吸光度线性良好;Fig. 2 is the chlorogenic acid standard curve of the n-butanol phase extract of sunflower disc of the present invention, illustrating that the chlorogenic acid concentration and the absorbance linearity are good in the range of 0~128ug/ml;
图3本发明的葵花盘正丁醇相提取物对大鼠胸主动脉具有舒张作用,并且其舒张血管作用呈现浓度依赖性,舒张作用效果较芦丁和绿原酸强;Fig. 3 Sunflower disc n-butanol phase extract of the present invention has relaxation effect on rat thoracic aorta, and its vasodilation effect is concentration-dependent, and the relaxation effect is stronger than rutin and chlorogenic acid;
图4本发明的葵花盘正丁醇相提取物的舒张血管主要通过NO途径。Fig. 4 The vasodilation of the n-butanol phase extract of the sunflower disc of the present invention is mainly through the NO pathway.
具体实施方式Detailed ways
实施例一 葵花盘正丁醇相的提取和定量分析Example 1 Extraction and quantitative analysis of n-butanol phase of sunflower plate
1.材料与方法1. Materials and methods
1.1材料1.1 Materials
葵花盘,购买产地为河北国安的栽培品种,经上海中医药大学教学实验中心可燕教授鉴定为菊科向日葵属向日葵(Helianthus annuus L.);芦丁、绿原酸标准品(上海源叶生物科技有限公司);75%乙醇、正丁醇(国药集团化学试剂有限公司);722可见光分光光度计(上海精密仪器有限公司);鼓风干燥箱(上海精宏实验设备有限公司)。Sunflower plate, purchased from Guoan, Hebei, was identified as Asteraceae Helianthus annuus L. by Professor Ke Yan of the Teaching and Experiment Center of Shanghai University of Traditional Chinese Medicine; rutin and chlorogenic acid standard (Shanghai Yuanye Biological Technology Co., Ltd.); 75% ethanol, n-butanol (Sinopharm Group Chemical Reagent Co., Ltd.); 722 visible light spectrophotometer (Shanghai Precision Instrument Co., Ltd.); Blast drying oven (Shanghai Jinghong Experimental Equipment Co., Ltd.).
1.2方法1.2 Methods
1.2.1葵花盘正丁醇相的提取1.2.1 Extraction of n-butanol phase of sunflower plate
采集来的新鲜葵花盘至鼓风干燥箱中60℃烘干,直接粉碎机粉碎;取1kg葵花盘粉末,将葵花盘粉碎,通过回流装置以75%乙醇提取;将提取物旋蒸、离心去沉淀;石油醚—乙酸乙酯—正丁醇依次萃取,石油醚与乙酸乙酯萃取保留的是下层液体,最后加入正丁醇,静置后分层,保留其上层提取液;将所得上层提取液旋蒸、离心去沉淀,得到其正丁醇相提取物1.024克,配制成1mg/mL,用于葵花盘正丁醇相提取物中总黄酮和绿原酸的定量分析。The collected fresh sunflower discs were dried at 60°C in a blast drying oven, and directly pulverized by a pulverizer; 1 kg of sunflower disc powder was taken, the sunflower discs were pulverized, and extracted with 75% ethanol through a reflux device; the extract was spun and centrifuged to remove Precipitation; petroleum ether-ethyl acetate-n-butanol is extracted successively, and petroleum ether and ethyl acetate are extracted to retain the lower layer liquid, and finally n-butanol is added, and the layers are separated after standing, and the upper layer extract is retained; the obtained upper layer is extracted The liquid was rotary evaporated and centrifuged to remove the precipitation to obtain 1.024 g of the n-butanol phase extract, which was formulated into 1 mg/mL for quantitative analysis of total flavonoids and chlorogenic acid in the n-butanol phase extract of sunflower disc.
1.2.2葵花盘正丁醇相提取物中的总黄酮定量分析1.2.2 Quantitative analysis of total flavonoids in the n-butanol phase extract of sunflower disc
1.2.2.1芦丁标准曲线的制作1.2.2.1 Preparation of rutin standard curve
准确称取芦丁标准品10mg,用90%乙醇溶解并定容至10m L,置于棕色瓶中4℃保存备用(1000μg/m L)。分别吸取标准品溶液0.1、0.2、0.4、0.8、0.16、0.32、0.64mL于10m L容量瓶中,加入0.3mL5%NaNO2溶液,混合均匀,6min后加0.3mL10%Al(NO3)3,混合均匀后静置6min,然后加入4mL 4%NaOH溶液,静置15min后用90%乙醇溶液定容至10mL,混匀,15min后于510nm处测定吸光值。以芦丁浓度(X)对吸光度(Y)进行线性回归分析,绘制芦丁标准曲线。Accurately weigh 10 mg of rutin standard, dissolve it with 90% ethanol and dilute to 10 mL, and store it in a brown bottle at 4°C for future use (1000 μg/mL). Pipette 0.1, 0.2, 0.4, 0.8, 0.16, 0.32, 0.64 mL of standard solution into a 10 mL volumetric flask, add 0.3 mL of 5% NaNO 2 solution, mix well, add 0.3 mL of 10% Al(NO3) 3 after 6 minutes, and mix After standing for 6 minutes, add 4 mL of 4% NaOH solution, and after standing for 15 minutes, dilute to 10 mL with 90% ethanol solution, mix well, and measure the absorbance at 510 nm after 15 minutes. A linear regression analysis was performed on the absorbance (Y) with the concentration of rutin (X), and the standard curve of rutin was drawn.
1.2.2.2葵花盘正丁醇相提取物中的总黄酮定量分析1.2.2.2 Quantitative analysis of total flavonoids in the n-butanol phase extract of sunflower disc
上述1.2.1中提取液稀释后,参照标准曲线的制作方法,分别按比加入5%NaNO2溶液、10%Al(NO3)3和4%NaOH溶液,定容制成样品液,在510nm处测其吸光度。提取率计算公式为:After diluting the extract in 1.2.1 above, referring to the preparation method of the standard curve, add 5% NaNO 2 solution, 10% Al(NO 3 ) 3 and 4% NaOH solution according to the ratio, make the sample solution at a constant volume, at 510nm Measure its absorbance. The extraction rate calculation formula is:
W=C×V×n/mW=C×V×n/m
其中:C-样品的浓度,根据标准曲线算出;V-样品稀释后的体积;Among them: C - the concentration of the sample, calculated according to the standard curve; V - the volume of the sample after dilution;
n-稀释的倍数;m-样品的质量。n-dilution factor; m-sample mass.
1.2.3葵花盘正丁醇相提取物中的绿原酸定量分析1.2.3 Quantitative analysis of chlorogenic acid in the n-butanol phase extract of sunflower disc
1.2.3.1绿原酸标准曲线的制作1.2.3.1 Preparation of chlorogenic acid standard curve
精密称取绿原酸对照品5.12mg置于10ml棕色容量瓶中,加入50%甲醇溶液定容至刻度,制成浓度为512μg/ml的绿原酸对照品溶液(10℃以下保存)。分别取绿原酸标准品溶液0.039ml、0.078ml、0.156ml、0.313ml、0.625ml、1.25ml、2.5m、l5ml于10ml棕色容量瓶中,加50%甲醇定容,配成浓度为2、4、8、16、32、64、128、256μg/ml的绿原酸标准品溶液,50%甲醇为空白对照。327nm波长下测不同浓度标准品溶液的吸光度值,以绿原酸浓度(X)对吸光度(Y)进行线性回归分析,绘制绿原酸标准曲线。Precisely weigh 5.12 mg of chlorogenic acid reference substance into a 10 ml brown volumetric flask, add 50% methanol solution to the mark, and prepare a chlorogenic acid reference substance solution with a concentration of 512 μg/ml (stored below 10°C). Take 0.039ml, 0.078ml, 0.156ml, 0.313ml, 0.625ml, 1.25ml, 2.5m, and 15ml of chlorogenic acid standard solution in a 10ml brown volumetric flask, add 50% methanol to the volume, and prepare a concentration of 2, 4, 8, 16, 32, 64, 128, 256 μg/ml of chlorogenic acid standard solution, 50% methanol as blank control. Measure the absorbance values of different concentrations of standard solution at 327nm wavelength, perform linear regression analysis on the absorbance (Y) of the chlorogenic acid concentration (X), and draw the chlorogenic acid standard curve.
1.2.3.2葵花盘正丁醇相提取物中的绿原酸定量分析1.2.3.2 Quantitative analysis of chlorogenic acid in the n-butanol phase extract of sunflower disc
上述1.2.1中提取液稀释后,精密称取葵花盘正丁醇相提取物样品5mg置于10ml棕色容量瓶中,加入50%甲醇溶液定容至刻度,制成浓度为500μg/ml的样品溶液。在327nm处测其吸光度。提取率计算公式为:After diluting the extract in 1.2.1 above, accurately weigh 5 mg of the n-butanol phase extract sample of sunflower disc and place it in a 10 ml brown volumetric flask, add 50% methanol solution to the mark, and prepare a sample with a concentration of 500 μg/ml solution. Its absorbance was measured at 327 nm. The extraction rate calculation formula is:
W=C×V×n/mW=C×V×n/m
其中:C-样品的浓度,根据标准曲线算出;V-样品稀释后的体积;Among them: C - the concentration of the sample, calculated according to the standard curve; V - the volume of the sample after dilution;
n-稀释的倍数;m-样品的质量。n-dilution factor; m-sample mass.
2.结果2. Results
2.1芦丁浓度在0~640ug/ml范围内与吸光度线性良好。标准曲线为y=0.0013x+0.0429。见表1和图1。2.1 The rutin concentration has a good linearity with the absorbance in the range of 0-640ug/ml. The standard curve is y=0.0013x+0.0429. See Table 1 and Figure 1.
表1 芦丁标准曲线Table 1 Standard curve of rutin
2.2根据2.1中标准曲线,代入得葵花盘正丁醇相提取物中的总黄酮含量=17.1±0.2wt%。2.2 According to the standard curve in 2.1, substitute the total flavonoid content in the n-butanol phase extract of sunflower disc=17.1±0.2wt%.
2.3绿原酸浓度在0~128ug/ml范围内与吸光度线性良好。标准曲线为y=0.0177x+0.1827。见表2和图2。2.3 The concentration of chlorogenic acid has a good linearity with absorbance in the range of 0~128ug/ml. The standard curve is y=0.0177x+0.1827. See Table 2 and Figure 2.
表2 绿原酸标准曲线Table 2 Standard curve of chlorogenic acid
2.4根据2.3中标准曲线,代入得葵花盘正丁醇相提取物中的绿原酸含量=6.7±0.1wt%。2.4 According to the standard curve in 2.3, substitute the chlorogenic acid content in the n-butanol phase extract of sunflower disc=6.7±0.1wt%.
实施例二 葵花盘正丁醇相提取物的舒张血管作用研究Example 2 Study on the vasodilatory effect of n-butanol phase extract of sunflower disc
1.材料与方法1. Materials and methods
1.1材料1.1 Materials
乙酰胆碱(Acetylcholine,ACh)、苯肾上腺素(Phenylephrine,PE)、硝普钠(Sodium Nitroprusside,SNP)等均购于Sigma公司,NaCl等无机试剂为国产分析纯。Kreb-Henseleit(K-H)液(mmol·L-1):NaCl 118,KCl 4.7,KH2PO4 1.2,MgCl2 1.2,NaHCO3 25,CaCl2 2.5,Glucose 11,PH=7.4)。动物:200±20g,大鼠30只,购买于上海斯莱克实验动物有限公司,饲养于上海中医药大学动物实验中心。分液漏斗、解剖板、大头钉、解剖剪、镊子、棉球(脱脂棉)、培养皿等。PowerLab八通道多功能生理记录仪(AD Instruments公司,澳大利亚)。Acetylcholine (ACh), phenylephrine (Phenylephrine, PE), Sodium Nitroprusside (SNP), etc. were purchased from Sigma Company, and inorganic reagents such as NaCl were of domestic analytical grade. Kreb-Henseleit (K-H) solution (mmol·L-1): NaCl 118, KCl 4.7, KH2PO4 1.2, MgCl2 1.2,
1.2方法1.2 Methods
1.2.1胸主动脉环的制备1.2.1 Preparation of thoracic aortic rings
大鼠麻醉处死,迅速取出胸主动脉置于4℃K-H液中,剥除周围结缔组织后制成2-3mm的血管环。将血管环悬挂于4mL K-H液的浴槽内,37℃恒温,并持续通入95%O2+5%CO2的混合气体。The rats were sacrificed by anesthesia, and the thoracic aorta was quickly taken out and placed in KH solution at 4°C, and the surrounding connective tissue was stripped to make a 2-3mm vascular ring. The vascular ring was suspended in a bath of 4 mL KH solution at a constant temperature of 37°C, and a mixture of 95% O 2 +5% CO 2 was continuously fed.
每个血管环给予2.0g拉力,每15min更换K-H液一次,平衡60min。以60mmol·L-1的KCl预收缩两次,以诱发最大收缩度,用K-H液洗脱拉力稳定后,加入10-6mol·L-1的PE收缩,待拉力达坪值后,加入10-5mol/L Ach,若血管舒张达80%以上,可认为内皮完整,可用于下一步实验。Each vascular ring was given a pulling force of 2.0g, KH solution was replaced every 15min, and it was balanced for 60min. Pre-contract twice with 60 mmol·L -1 KCl to induce the maximum shrinkage. After eluting with KH solution, after the tensile force is stable, add 10 -6 mol·L -1 PE to shrink. After the tensile force reaches the plateau value, add 10 -5 mol/L Ach, if the vasodilation is more than 80%, the endothelium can be considered intact and can be used in the next experiment.
1.2.2葵花盘正丁醇相提取物对大鼠胸主动脉内皮依赖舒张的作用1.2.2 The effect of sunflower disc n-butanol phase extract on endothelium-dependent relaxation of rat thoracic aorta
制成内皮完整的大鼠胸主动脉血管环,等剂量的PE收缩,加入不同浓度葵花盘正丁醇相提取物(按实施例一制备),观察不同浓度梯度组对胸主动脉内皮依赖舒张的作用。根据以上实验步骤进行重复实验3次以上。Rat thoracic aortic vascular rings with intact endothelium were prepared, and equal doses of PE were used to contract, and different concentrations of sunflower disc n-butanol phase extract (prepared according to Example 1) were added to observe the effect of different concentration gradient groups on thoracic aortic endothelium-dependent relaxation. effect. Repeat the experiment more than 3 times according to the above experimental steps.
1.2.3葵花盘正丁醇相提取物对大鼠胸主动脉内皮依赖舒张的机制1.2.3 Mechanism of n-butanol phase extract of sunflower disc on endothelium-dependent relaxation of rat thoracic aorta
制成内皮完整的大鼠胸主动脉血管环,分别用L-NAME(0.1mmol·L-1)、吲哚美辛(0.1mmol·L-1)、TEA(5mmol·L-1)预处理20min,以PE预收缩,加入葵花盘正丁醇相提取物(按实施例一制备)观察其作用,对照组加入相同剂量K-H液。Rat thoracic aortic vascular rings with intact endothelium were prepared and pretreated with L-NAME (0.1mmol·L -1 ), indomethacin (0.1mmol·L -1 ) and TEA (5mmol·L -1 ), respectively 20min, pre-shrink with PE, add the n-butanol phase extract of sunflower disc (prepared according to Example 1) to observe its effect, and add the same dose of KH solution to the control group.
2结果2 results
2.1本发明的葵花盘正丁醇相提取物对大鼠胸主动脉具有舒张作用,并且其舒张血管作用呈现浓度依赖性,作用效果优于其含有的芦丁和绿原酸(见表3和图3)。2.1 Sunflower disc n-butanol phase extract of the present invention has diastolic effect on rat thoracic aorta, and its vasodilatation effect is concentration-dependent, and the effect is better than the rutin and chlorogenic acid it contains (see Table 3 and image 3).
表3 不同浓度葵花盘正丁醇相提取物对血管舒张的作用Table 3 Effects of different concentrations of sunflower disc n-butanol phase extract on vasodilation
与0.1mg/μL葵花盘正丁醇相比较,**P<0.01 ** P<0.01 compared to 0.1mg/μL sunflower dish n-butanol
2.2葵花盘正丁醇提取相对大鼠胸主动脉的舒张作用主要通过NO途径(见表4和图4)。2.2 The relaxation effect of n-butanol extraction from sunflower disc relative to rat thoracic aorta is mainly through the NO pathway (see Table 4 and Figure 4).
表4 不同浓度葵花盘正丁醇相提取物对血管舒张的作用Table 4 The effect of different concentrations of sunflower disc n-butanol phase extract on vasodilation
与0.1mg/μL葵花盘正丁醇相比较,**P<0.01 ** P<0.01 compared to 0.1mg/μL sunflower dish n-butanol
本发明所涉及的多个方面已做如上阐述。然而,应理解的是,在不偏离本发明精神之前提下,本领域专业人员可对其进行等同改变和修饰,所述改变和修饰同样落入本申请所附权利要求的覆盖范围。The various aspects involved in the present invention have been described above. However, it should be understood that equivalent changes and modifications may be made thereto by those skilled in the art without departing from the spirit of the present invention, which also fall within the scope of coverage of the appended claims of the present application.
Claims (3)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710352702.XA CN107198708B (en) | 2017-05-18 | 2017-05-18 | A kind of sunflower disc extract and its preparation method and use |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710352702.XA CN107198708B (en) | 2017-05-18 | 2017-05-18 | A kind of sunflower disc extract and its preparation method and use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN107198708A CN107198708A (en) | 2017-09-26 |
| CN107198708B true CN107198708B (en) | 2020-10-16 |
Family
ID=59905250
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710352702.XA Active CN107198708B (en) | 2017-05-18 | 2017-05-18 | A kind of sunflower disc extract and its preparation method and use |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107198708B (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6790465B2 (en) * | 2000-12-01 | 2004-09-14 | Snore-Fix, Inc. | Composition and method for treating snoring |
| CN103641717A (en) * | 2013-12-18 | 2014-03-19 | 中国农业科学院兰州畜牧与兽药研究所 | Method for extracting and separating chlorogenic acid from flower disk of sunflower in florescence |
| CN105920067A (en) * | 2016-05-06 | 2016-09-07 | 洮南市金塔生物科技有限公司 | Sunflower calathide extract containing polysaccharide, flavonoid and alkaloid and preparation method of sunflower calathide extract |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080206161A1 (en) * | 2002-10-25 | 2008-08-28 | Dov Tamarkin | Quiescent foamable compositions, steroids, kits and uses thereof |
-
2017
- 2017-05-18 CN CN201710352702.XA patent/CN107198708B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6790465B2 (en) * | 2000-12-01 | 2004-09-14 | Snore-Fix, Inc. | Composition and method for treating snoring |
| CN103641717A (en) * | 2013-12-18 | 2014-03-19 | 中国农业科学院兰州畜牧与兽药研究所 | Method for extracting and separating chlorogenic acid from flower disk of sunflower in florescence |
| CN105920067A (en) * | 2016-05-06 | 2016-09-07 | 洮南市金塔生物科技有限公司 | Sunflower calathide extract containing polysaccharide, flavonoid and alkaloid and preparation method of sunflower calathide extract |
Non-Patent Citations (1)
| Title |
|---|
| 向日葵花盘中有效化学成分分析及抗氧化性测定;索金玲;《中国优秀硕士学位论文全文数据库 农业科技辑》;20110215(第2期);第3页第4段、第17页第4段、第49页第1段、第60页最后1段至第61页第1段 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN107198708A (en) | 2017-09-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104341430B (en) | A kind of soil Radix Glycyrrhizae A and extracting method thereof and purposes | |
| Júnior et al. | Processing and quality control of herbal drugs and their derivatives | |
| Jhade et al. | Pharmacognostic Screening, Phytochemical Evaluation and In—Vitro free radical Scavenging Activity of Acacia leucophloea Root | |
| Raman et al. | Application of anatomy and HPTLC in characterizing species of Dioscorea (Dioscoreaceae) | |
| Stefanis et al. | Exploring the chemical content of Primula veris L. subsp. veris wild-growing populations along a climate gradient: An HPLC-PDA-MS quality assessment of flowers, leaves and roots for sustainable exploitation | |
| CN107198708B (en) | A kind of sunflower disc extract and its preparation method and use | |
| CN105712963B (en) | A kind of coumarin dimer and its preparation method and application | |
| CN105712844A (en) | Cadinane sesquiterpene Saliciforliusin A and preparation method and application thereof | |
| CN105004726A (en) | Phellinus igniarius identification method | |
| CN104502511B (en) | The detection method of four kinds of gradient elutions in Allium wallichii | |
| Kumudhaveni et al. | Pharmacognostical and phytochemical standardization of seeds of Strychnos potatorum Linn.(Loganiaceae) | |
| Sheikh et al. | Formulation and Evaluation of Anti microbial Dusting Powder. | |
| Itzhanova et al. | Histochemical Analysis of Plant Raw Materials of Anabasis salsa Growing in the Territory of The Central Kazakhstan | |
| Huang et al. | Pharmacognostical study of Croton Crassifolius Geisel | |
| Suman et al. | Phytochemical screening from leaf extracts of the plant Coleus forskohlii (Brig) collected from the Ananthagiri forest area, Rangareddy District, Andhra Pradesh, India | |
| Mehta et al. | Physico-chemical analysis of some temperate Himalayan Swertia species | |
| Wang et al. | Study on the cultivation and potential medicinal value of the newly recorded Eulophia graminea Lindley from Fujian species | |
| Adamu et al. | Exploring the Phytochemical Properties of Prosopis africana Plants and Assessing their Antimicrobial Potential Against Selected Clinical Strains | |
| CN1814011B (en) | A kind of preparation method of injection for treating upper respiratory tract infection | |
| Kurkin et al. | Development of a Method of Quantitative Determination of Total Flavonoids in the Leaves of Myrtus communis | |
| Rajeshwar et al. | Microscopical and physicochemical studies of indigofera barberi (fabaceae) stem | |
| Sharma et al. | PHYSICOCHEMICAL AND PRELIMINARY PHYTOCHEMICAL EVALUATION OF LEAVES OF FIVE COMMON INDIGENOUS WEEDS FOUND IN CENTRAL INDIA. | |
| Wang et al. | Study on the extraction of flavonoids from Artemisia integrifolia and its anti-lung cancer activity | |
| Dutta et al. | Screening of Phytochemicals in Shoot Cultures of Endangered Herb Gentiana Kurroo Royle | |
| Pelo | Phytochemical analysis and antibacterial properties of Zantedeschia aethiopica |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |